<DOC>
	<DOC>NCT02696785</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biological disease-modifying anti-rheumatic drugs (bDMARDs)-naive participants with radiographic axial spondyloarthritis (rad-axSpA).</brief_summary>
	<brief_title>A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Are ambulatory. Diagnosis of radiographic axial spondyloarthritis (radxSpA) with sacroiliitis defined radiographically according to the modified New York criteria. Participants have a history of back pain â‰¥3 months with age at onset &lt;45 years. In the past had an inadequate response to at least 2 nonsteroidal antiinflammatory drugs (for duration 4 weeks) or cannot tolerate NSAIDS. If taking NSAIDS be on a stable dose for at least 2 weeks prior to randomization. Have a history of prior therapy for axSpa for at least 12 weeks prior to screening. Have total ankylosis of the spine. Have received any prior, or are currently receiving, treatment with biologics, tumor necrosis factor inhibitors or other immunomodulatory agents. Have recently received a live vaccine within 12 weeks or have had a vaccination with Bacillus CalmetteGuerin (BCG) within the past year. Have an ongoing or serious infection within the last 12 weeks or evidence of active tuberculosis. Have a compromised immune system. Have any other serious and/or uncontrolled diseases. Have either a current diagnosis or a recent history of malignant disease. Have had major surgery within 8 weeks of baseline, or will require surgery during the study. Are pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>